Committee for Advanced Therapies (CAT)
Minutes of the meeting on 06-08 September 2023

Chair: Ilona Reischl; Vice-Chair: Kieran Breen

Disclaimers
Some of the information contained in these minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CAT meeting reports once the procedures are finalised.

Of note, these minutes are a working document primarily designed for CAT members and the work the Committee undertakes.

Note on access to documents
Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to ongoing procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).
# Table of contents

## 1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts ....... 6  
1.2. Adoption of agenda ................................................................................................ 6  
1.3. Adoption of the minutes ......................................................................................... 6

## 2. Evaluation of ATMPs

2.1. Opinions ................................................................................................................. 6  
2.2. Oral explanations ................................................................................................... 6  
2.3. Day 180 list of outstanding issues .......................................................................... 7  
2.3.1. Exagamglogene autotemcel - PRIME - Orphan - EMEA/H/C/005763 ................. 7  
2.4. Day 120 list of questions ........................................................................................ 7  
2.4.1. Fidanacogene elaparvovec - PRIME - Orphan - EMEA/H/C/004774 ................... 7  
2.5. Day 80 assessment reports .................................................................................... 7  
2.6. Update on ongoing initial applications ............................................................... 7  
2.7. New applications .................................................................................................... 7  
2.8. Withdrawal of initial marketing authorisation application .................................... 7  
2.9. Re-examination of initial application procedures under Article 9(2) of Regulation No. 726/2004 ............................................................................................................... 8

## 2.10. Companion diagnostics....................................................................................... 8

2.10.1. Initial consultation ............................................................................................. 8  
2.10.2. Follow-up consultation ..................................................................................... 8

## 2.11. Type II variations and variations of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008 ......................................................................................... 8

2.11.1. Alofisel - darvadstrocel - Orphan - EMEA/H/C/004258/II/0044/G ....................... 8  
2.11.2. Breyanzi - lisocabtagene maraleucel / lisocabtagene maraleucel - EMEA/H/C/004731/II/0003 .......................................................... 8  
2.11.3. Breyanzi - lisocabtagene maraleucel / lisocabtagene maraleucel - EMEA/H/C/004731/II/0014 .......................................................... 9  
2.11.4. Breyanzi - lisocabtagene maraleucel / lisocabtagene maraleucel - EMEA/H/C/004731/II/0021 .......................................................... 9  
2.11.5. Breyanzi - lisocabtagene maraleucel / lisocabtagene maraleucel - EMEA/H/C/004731/II/0026/G .......................................................... 9  
2.11.6. CARVYKTI - ciltacabtagene autoleucel - Orphan - EMEA/H/C/005095/II/0021 ........... 10  
2.11.7. Imlygic - talimogene laherparepvec - EMEA/H/C/002771/II/0063 ...................... 10  
2.11.8. Imlygic - talimogene laherparepvec - EMEA/H/C/002771/II/0064 ...................... 11  
2.11.9. Kymriah - tisagenlecleucel - Orphan - EMEA/H/C/004090/II/0072 .................... 11  
2.11.10. Libmeldy - atidarsagene autotemcel - Orphan - EMEA/H/C/005321/II/0015 ............ 11  
2.11.11. Upstaza - eladocagene exuparvovec - Orphan - EMEA/H/C/005352/II/0013 ............ 11  
2.11.12. Zolgensma - onasemnogene abeparvovec - Orphan - EMEA/H/C/004750/II/0040 ........... 12
2.12. Extension applications

2.13. Other Post-Authorisation Activities

2.13.1. CARVYKTI - ciltaclabtagene autoleucel - Orphan - EMEA/H/C/005095/MEA/007.2

2.13.2. Kymriah - tisagenlecleucel - Orphan - EMEA/H/C/004090/LEG/021

2.13.3. Upstaza - eladocagene exuparvovec - Orphan - EMEA/H/C/005352

2.14. GMP and GCP inspections requests

3. Certification of ATMPs

3.1. Opinion

3.2. Day 60 Evaluation Reports

3.3. New Applications

4. Scientific Recommendation on Classification of ATMPs

4.1. New requests – Appointment of CAT Coordinator

4.1.1. Devitalized cell-derived cartilaginous tissue

4.2. Day 30 ATMP scientific recommendation

4.2.1. Allogeneic ex-vivo expanded pluripotent stem cell-derived cardiac ventricular progenitor cells

4.2.2. Allogeneic ex-vivo expanded pluripotent stem cell-derived photoreceptor progenitor cells

4.2.3. Allogeneic genetically modified human induced pluripotent stem cell-derived retinal pigment epithelial cells

4.2.4. Autologous cultured fibroblasts

4.2.5. Secretome (conditioned medium) from donor bone marrow mesenchymal stem cells (MSCs) containing cytokines, growth factors, proteins and extracellular vesicles

4.3. Day 60 revised scientific recommendation (following list of questions)

4.4. Finalisation of procedure

4.5. Follow-up and guidance

5. Scientific Advice

5.1. New requests - appointment of CAT Rapporteurs

5.1.1. Ongoing scientific advice procedures - Appointment of CAT Peer Reviewers

5.1.2. Scientific advice procedures starting at the next SAWP meeting

5.2. Procedures discussed at SAWP – 1st reports, D40 JRs, LoIs

5.3. Finalisation of D70 procedures – feedback from the discussion meeting

5.4. Final Advice Letters for procedures finalised the previous month

6. Pre-Authorisation Activities

6.1. Paediatric investigation plans

6.2. ITF briefing meetings in the field of ATMPs

6.3. Priority Medicines (PRIME) – Eligibility requests
6.3.1. Month 0 - Start of the procedure ................................................................. 17
6.3.2. Month 1 – Discussion of eligibility ........................................................... 17
6.3.3. Month 2 – Recommendation of eligibility ............................................... 17
6.3.4. Ongoing support ....................................................................................... 17

7. Organisational, regulatory and methodological matters 18

7.1. Mandate and organisation of the CAT ......................................................... 18
7.1.1. CAT membership ....................................................................................... 18
7.1.2. Vote by proxy ............................................................................................ 18
7.1.3. CAT Strategic Review & Learning meeting (SRLM) under the Spanish presidency, 25-27 October 2023 Madrid (Spain) .................................................. 18
7.1.4. CAT 15th anniversary ............................................................................... 18

7.2. Coordination with EMA Scientific Committees .......................................... 18
7.2.1. Update from the PCWP-HCPWP ............................................................... 18
7.2.2. CAT-COMP working group meeting ...................................................... 19

7.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups 19
7.3.1. Patient Experience Data (PED) project .................................................... 19
7.3.2. Streamlining of BWP operations ............................................................. 19

7.4. Cooperation with the EU regulatory network ........................................... 19
7.4.1. Support to member states for the assessment of ATMP Marketing Authorisation Applications ................................................................. 19

7.5. Cooperation with international regulators ............................................... 20
7.5.1. ATMP cluster teleconference with US-FDA, Health Canada and PMDA (Japan) ................................................................. 20
7.5.2. WHO considerations in developing a regulatory framework for human cells and tissues and for advanced therapy medicinal products ................................................................. 20
7.5.3. International Pharmaceutical Regulatory Programme (IPRP): Gene therapy and Cell therapy working groups ................................................................. 20

7.6. CAT work plan ............................................................................................ 20
7.6.1. CAT work plan for 2024 .......................................................................... 20
7.6.2. CAT Stakeholder meeting of 16 May 2023 ............................................... 21

7.7. Planning and reporting .............................................................................. 21
7.7.1. Business Pipeline Report ........................................................................ 21

7.8. Others .......................................................................................................... 21
7.8.1. FDA Public workshop: Assessing genetic heterogeneity in the context of genome editing off-targets in gene therapy products ................................................................. 21
7.8.2. CASSS China – 3rd CMC Strategy Forum for Biological Products (12-13 October 2023) ................................................................. 21
7.8.3. FDA Considerations for the Use of Real-World Data and Real-World Evidence to Support Regulatory Decision-Making for Drug and Biological Products ................................................................. 21
<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>8.</td>
<td>Any other business</td>
<td>22</td>
</tr>
<tr>
<td>9.</td>
<td>List of participants</td>
<td>22</td>
</tr>
<tr>
<td>10.</td>
<td>Explanatory notes</td>
<td>26</td>
</tr>
</tbody>
</table>
1. **Introduction**

1.1. **Welcome and declarations of interest of members, alternates and experts**

The Chairperson opened the meeting by welcoming all participants. The meeting was held remotely.

In accordance with the Agency’s policy on handling of declarations of interests of scientific committees’ members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and on the topics in the agenda of the current meeting, the Committee Secretariat announced that no restriction in the involvement of meeting participants for agenda topics was identified.

Participants were asked to declare any changes, omissions or errors to their declared interests and/or additional restrictions concerning the matters for discussion. No new or additional interests or restrictions were declared. Restrictions applicable to this meeting are captured in the List of participants included in the minutes.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure. All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.

The Chair thanked the departing member from Hungary for her contributions to the Committee.

The EMA secretariat announced the names of the Committee members who delegated their vote via proxy and the Committee members who received such proxy.

1.2. **Adoption of agenda**

The CAT agenda for 06-08 September 2023 meeting was adopted.

1.3. **Adoption of the minutes**

The CAT minutes of the 12-14 July 2023 and 09-11 August (by written procedure) meetings were adopted.

2. **Evaluation of ATMPs**

2.1. **Opinions**

No items

2.2. **Oral explanations**

No items
2.3.  **Day 180 list of outstanding issues**

2.3.1. **Exagamglogene autotemcel - PRIME - Orphan - EMEA/H/C/005763**

Vertex Pharmaceuticals (Ireland) Limited; Treatment of transfusion-dependent β-thalassemia and sickle cell disease

Scope: Day 180 list of outstanding issues

**Action:** for adoption

List of questions adopted on 17.05.2023.

The Rapporteur presented the outcome of the assessment of responses to the list of questions. Feedback was provided from the discussions in the Biologics Working Party.

The list of outstanding issues was adopted.

2.4.  **Day 120 list of questions**

2.4.1. **Fidanacogene elaparvovec - PRIME - Orphan - EMEA/H/C/004774**

Pfizer Europe MA EEIG; Indicated for the treatment of severe and moderately severe haemophilia B

Scope: Day 120 list of questions

**Action:** for adoption

The Rapporteur and CoRapporteur presented the outcome of the assessment of the marketing authorisation application. The outcome of the quality assessment was also discussed in the Biologics Working Party.

The list of questions was adopted.

2.5.  **Day 80 assessment reports**

No items

2.6.  **Update on ongoing initial applications**

No items

2.7.  **New applications**

2.8.  **Withdrawal of initial marketing authorisation application**

No items
2.9. Re-examination of initial application procedures under Article 9(2) of Regulation No. 726/2004

No items

2.10. Companion diagnostics

2.10.1. Initial consultation

No items

2.10.2. Follow-up consultation

No items

2.11. Type II variations and variations of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

2.11.1. Alofisel - darvadstrocel - Orphan - EMEA/H/C/004258/II/0044/G

Takeda Pharma A/S
Rapporteur: Maria Luttgen
Scope: Safety, Opinion

Grouped application comprising one type II variation and two type IB as follows:
- Update of section 4.8 of the SmPC in order to update the summary of the safety profile and to add anal abscess, proctalgia and anal fistula to the list of adverse drug reactions on post-marketing experience following the assessment of R/0036 based on a review of the MAH's Global Safety Database.
- Update of section 4.2 of the SmPC in order to add the term Perilesional as an EDQM term, following the assessment of R/0036.
- Update of sections 1, 2.2, 3, 4.2, 6.5 and 6.6 of the SmPC in order to replace the term "suspension for injection" for "dispersion for injection", following the assessment of R/0036.

The Annex A, Package Leaflet and Labelling are updated in accordance.

**Action:** for adoption

Request for supplementary information adopted on 17.05.2023.

The Rapporteur presented the outcome of the assessment and the changes that were implemented to the product information. The opinion was adopted.

2.11.2. Breyanzi - lisocabtagene maraleucel / lisocabtagene maraleucel - EMEA/H/C/004731/II/0003

Bristol-Myers Squibb Pharma EEIG
Rapporteur: Concetta Quintarelli
Scope: Quality, Opinion

**Action:** for adoption

Request for supplementary information adopted on 07.10.2022 and 15.07.2022.
The opinion was adopted.

### 2.11.3. Breyanzi - lisocabtagene maraleucel / lisocabtagene maraleucel - EMEA/H/C/004731/II/0014

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Concetta Quintarelli, PRAC Rapporteur: Gabriele Maurer

Scope: Clinical, Opinion

Update of section 5.1 of the SmPC in order to update efficacy information based on final results from studies 017001 and JCAR-017-BCM-001 listed as obligations in the Annex II. These studies aimed to further characterise the long-term efficacy and safety of Breyanzi in patients treated with relapsed or refractory DLBCL, PMBCL, FL3B after two or more lines of systemic therapy. Study 017001 is a phase 1, open-label, single-arm, multicohort, multicentre, seamless design trial, while study JCAR-017-BCM-001 is a phase 2, open-label, single-arm, multicohort, multicentre trial. The Annex II is updated accordingly. The RMP version 3.0 has also been submitted.

**Action:** for adoption

Request for supplementary information adopted on 24.03.2023.
The Rapporteur presented the outcome of the assessment and the changes that were implemented to the product information. The opinion was adopted.

### 2.11.4. Breyanzi - lisocabtagene maraleucel / lisocabtagene maraleucel - EMEA/H/C/004731/II/0021

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Concetta Quintarelli

Scope: Quality, Opinion

**Action:** for adoption

The opinion was adopted.

### 2.11.5. Breyanzi - lisocabtagene maraleucel / lisocabtagene maraleucel - EMEA/H/C/004731/II/0026/G

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Concetta Quintarelli

Scope: Quality, Request for supplementary information
**Action:** for adoption

The request for supplementary information was adopted.

---

**2.11.6. CARVYKTI - cilta-cabtagene autoleucel - Orphan - EMEA/H/C/005095/II/0021**

Janssen-Cilag International NV

Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Jo Robays

Scope: Clinical, Request for supplementary information

Extension of indication to include treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 1 prior therapy, including an immunomodulatory agent (IMiD) and a protease inhibitor (PI), have demonstrated disease progression on or after the last therapy and are refractory to lenalidomide for CARVYKTI, based on interim results from study MMY3002 listed as a specific obligation (SOB/006) in the Annex II. This is an ongoing, Phase 3, randomised, open-label, multicentre study to determine whether treatment with cila-cel provides an efficacy benefit compared to standard therapy in participants with relapsed and lenalidomide-refractory multiple myeloma. As a consequence, sections 4.1, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 4.1 of the RMP has also been submitted. In addition, the MAH took the opportunity to update Annex II of the product information (PI). As part of the application the MAH is requesting a 1-year extension of the market protection.

**Action:** for adoption

The Rapporteur presented the evaluation of this application for extension of indication to a second line setting.

The request for supplementary information was adopted.

---

**2.11.7. Imlygic - talimogene laherparepvec - EMEA/H/C/002771/II/0063**

Amgen Europe B.V.

Rapporteur: Maija Tarkkanen

Scope: Clinical, Opinion

Submission of the final report from study 20110261 listed as a category 3 study in the RMP. This is a Phase I, multi-centre, open-label, dose de-escalation study to evaluate the safety and efficacy of talimogene laherparepvec in paediatric subjects with advanced noncentral nervous system tumours that are amenable to direct injection.

**Action:** for adoption

The final report of the study 20110261 did not result in new safety issues and the benefit risk profile is unchanged. There are no changes to the product information. The opinion was adopted.
2.11.8. **Imlygic - talimogene laherparepvec - EMEA/H/C/002771/II/0064**

Amgen Europe B.V.
Rapporteur: Maija Tarkkanen, PRAC Rapporteur: Gabriele Maurer
Scope: Safety, Opinion
Submission of an updated RMP version 11.0 in order to remove the important potential risk of 'talimogene laherparepvec-mediated anti-GM-CSF antibody response', based on the accumulated scientific and clinical data.

**Action:** for adoption

The opinion was adopted.

2.11.9. **Kymriah - tisagenlecleucel - Orphan - EMEA/H/C/004090/II/0072**

Novartis Europharm Limited
Rapporteur: Rune Kjeken
Scope: Quality, Request for supplementary information

**Action:** for adoption

The request for supplementary information was adopted.

2.11.10. **Libmeldy - atidarsagene autotemcel - Orphan - EMEA/H/C/005321/II/0015**

Orchard Therapeutics (Netherlands) B.V.
Rapporteur: Johannes Hendrikus Ovelgonne
Scope: Quality, Opinion

**Action:** for adoption

Request for supplementary information adopted on 16.06.2023.

The opinion was adopted.

2.11.11. **Upstaza - eladocagene exuparvovec - Orphan - EMEA/H/C/005352/II/0013**

PTC Therapeutics International Limited
Rapporteur: Maura O'Donovan
Scope: Quality, Request for supplementary information

**Action:** for adoption

The Rapporteur presented the outcome of the assessment of this variation.

The request for supplementary information was adopted.
2.11.12. Zolgensma - onasemnogene abeparvovec - Orphan - EMEA/H/C/004750/II/0040

Novartis Europharm Limited

Rapporteur: Johannes Hendrikus Ovelgonne, PRAC Rapporteur: Ulla Wändel Liminga

Scope: Safety, Opinion

Update of sections 4.4 and 5.1 of the SmPC in order to add a new warning and precaution capturing the theoretical risk of tumorigenicity as a result of vector integration and to include a new statement indicating random instances of vector integration are possible based on final results from studies 2220205 and 2220117, and literature. The Package Leaflet is updated accordingly. The RMP version 3 has also been submitted.

Action: for adoption


The opinion was adopted.

2.12. Extension applications

No items

2.13. Other Post-Authorisation Activities

2.13.1. CARVYKTI - ciltacabtagene autoleucel - Orphan - EMEA/H/C/005095/MEA/007.2

Janssen-Cilag International NV

Rapporteur: Jan Mueller-Berghaus

Scope: Pharmacovigilance, Opinion

MAH Response to MEA 007.1 [Study no: PCSONCA0014] as adopted in April 2023:
The MAH should target a minimum enrolment of 30 healthcare professionals (HCPs) in each role (physicians, nurses, pharmacists) to allow valid statistical analysis. The MAH should make sure that there are at least 30 HCPs in each role and continue to enrol centres until this target is achieved [From Initial MAA]

Action: for adoption

The Rapporteur’s assessment of the post-authorisation measure was adopted.

2.13.2. Kymriah - tisagenlecleucel - Orphan - EMEA/H/C/004090/LEG/021

Novartis Europharm Limited

Rapporteur: Rune Kjeken

Scope: Pharmacovigilance, Request for supplementary information

From EMEA/H/C/PSUSA/00010702/202208:
MAH's responses to supplementary information.
List of issues relates to potential secondary malignancy cases (PSUR 07 (reporting period

Committee for Advanced Therapies (CAT)
EMACAT/412887/2023
13-Aug-2021 to 12-Aug-2022))

**Action:** for adoption

The Rapporteur’s assessment of the post-authorisation measure was adopted.

### 2.13.3. Upstaza - eladocagene exuparvovec - Orphan - EMEA/H/C/005352

PTC Therapeutics International Limited

Rapporteur: Maura O'Donovan

Scope: EMA updates on the interaction with iNTD, as a possible data source for Upstaza

SOB PTC-AADC-MA-406

**Action:** for discussion

This is an update on post-authorisation measure MEA/007 (discussed at the March 2023 CAT meeting, agenda point 2.13.7). EMA provided feedback on the interaction with the iNTD registry holder, during which the expectations from EMA for a registry holder were clarified. CAT agreed for EMA to organise a meeting with the marketing authorisation holder and the registry holder.

CAT suggested to make an information package to explain what is expected from registry holders when involved in post-authorisation studies for ATMPs. This can potentially be included in the revision of the GVP module 5.

### 2.14. GMP and GCP inspections requests

No items

### 3. Certification of ATMPs

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

#### 3.1. Opinion

No items

#### 3.2. Day 60 Evaluation Reports

No items

#### 3.3. New Applications

No items
4. **Scientific Recommendation on Classification of ATMPs**

Timetable:
- Start of the procedure: 08.09.2023
- EMA Coordinator’s draft report: 19.09.2023
- CAT Coordinator’s comments: 27.09.2023
- Revised scientific recommendation: 29.09.2023
- CAT’s discussion of scientific recommendation: 06.10.2023

4.1. **New requests – Appointment of CAT Coordinator**

4.1.1. **Devitalized cell-derived cartilaginous tissue**

Bone substitute for maxillofacial and/or orthopaedic bone defects

Scope: Appointment of CAT Coordinator and adoption of timetable

**Action:** for adoption

The CAT coordinator was appointed.

4.2. **Day 30 ATMP scientific recommendation**

4.2.1. **Allogeneic ex-vivo expanded pluripotent stem cell-derived cardiac ventricular progenitor cells**

Intended for the treatment of chronic and acute heart disease
Scope: ATMP scientific recommendation

**Action:** for adoption

CAT discussed the classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 22.09.2023.

4.2.2. **Allogeneic ex-vivo expanded pluripotent stem cell-derived photoreceptor progenitor cells**

Intended for the treatment of retinitis pigmentosa

Scope: ATMP scientific recommendation

**Action:** for adoption

CAT discussed the classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 22.09.2023.

4.2.3. **Allogeneic genetically modified human induced pluripotent stem cell-derived retinal pigment epithelial cells**

Intended for the treatment of Stargardt indication

Scope: ATMP scientific recommendation
**Action**: for adoption

CAT discussed the classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 22.09.2023.

### 4.2.4. Autologous cultured fibroblasts

Intended for the treatment of scars and wounds

Scope: ATMP scientific recommendation

**Action**: for adoption

CAT discussed the classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 22.09.2023.

### 4.2.5. Secretome (conditioned medium) from donor bone marrow mesenchymal stem cells (MSCs) containing cytokines, growth factors, proteins and extracellular vesicles

Intended for the treatment of paediatric respiratory diseases called childhood interstitial lung disease (ChILD)

Scope: ATMP scientific recommendation

**Action**: for adoption

CAT discussed the classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 22.09.2023.

### 4.3. Day 60 revised scientific recommendation (following list of questions)

No items

### 4.4. Finalisation of procedure

No items

### 4.5. Follow-up and guidance

#### 4.5.1. Cells treated by extracorporeal photopheresis

CAT: Nancy De Bremaeker

Scope: Informal classification discussion on request of a member state

**Action**: for discussion

CAT discussed the question if the manipulation of (autologous) blood cells by extracorporeal photopheresis with psoralenes (8-MOP) and UV should be considered a substantial manipulation, and whether the treated cells should be considered as ATMPs.
CAT did recap the discussion in 2012, where it became clear that, at that time, there was no uniform classification in the EU. This was confirmed in a recent survey (conducted by the French authorities for tissues and cells and the European Commission, DG Santé of 22.04.2021) on Extracorporeal Chemotherapy procedures: in the majority of member states, such procedures were rather considered under the tissue and cell legislation (Directive 2004/23/EC). CAT members indicated the treatment with 8-MOP will mainly kill susceptible cells. It will also be very challenging or impossible to quality control the cells before being re-administered to the patient.

In absence of a harmonised classification of such products in the EU, the national authority might consider, as a pragmatic approach, to regulate these products under the tissue and cell legislation. That approach will also allow for products to be produced in a tissue establishment (TE) in one member state and transported to a TE in another member state.

5. Scientific Advice

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

5.1. New requests - appointment of CAT Rapporteurs

5.1.1. Ongoing scientific advice procedures - Appointment of CAT Peer Reviewers

Timetable:
- Start of procedure at SAWP: 28-31.08.2023
- Appointment of CAT Peer Reviewers: 06-08.09.2023
- SAWP first reports: 18.09.2023
- CAT Peer Reviewer comments (NC/C): 22.09.2023
- CAT Peer Reviewer comments (Q): 27.09.2023
- Discussion at SAWP: 25-28.09.2023
- Discussion at CAT and feedback to SAWP: 04-06.10.2023

5.1.2. Scientific advice procedures starting at the next SAWP meeting

Timetable:
- Start of procedure at SAWP: 25-28.09.2023
- Appointment of CAT Peer Reviewers: 04-06.10.2023
- SAWP first reports: 16.10.2023
- CAT Peer Reviewer comments (NC/C): 20.10.2023
- CAT Peer Reviewer comments (Q): 25.10.2023
- Discussion at SAWP: 23-23.10.2023
- Discussion at CAT and feedback to SAWP: 30-31.10.2023

5.2. Procedures discussed at SAWP – 1st reports, D40 JRs, LoIs

5.3. Finalisation of D70 procedures – feedback from the discussion meeting

No items
5.4. **Final Advice Letters for procedures finalised the previous month**

No items

6. **Pre-Authorisation Activities**

   Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

6.1. **Paediatric investigation plans**

   No items

6.2. **ITF briefing meetings in the field of ATMPs**

6.3. **Priority Medicines (PRIME) – Eligibility requests**

   6.3.1. **Month 0 – Start of the procedure**

   Timetable for assessment:
   - Procedure start: 28-31.08.2023
   - SAWP recommendation: 28.09.2023
   - CAT recommendation: 06.10.2023
   - CHMP adoption of report and final recommendation: 12.10.2023

   6.3.2. **Month 1 – Discussion of eligibility**

   No items

   6.3.3. **Month 2 – Recommendation of eligibility**

   No items

   6.3.4. **Ongoing support**

   No items
7. Organisational, regulatory and methodological matters

7.1. Mandate and organisation of the CAT

7.1.1. CAT membership

The Chair thanked Katalin Lenguel for her contribution as member for Hungary.

Action: for information

7.1.2. Vote by proxy

None

Action: for information

7.1.3. CAT Strategic Review & Learning meeting (SRLM) under the Spanish presidency, 25-27 October 2023 Madrid (Spain)

CAT: Sol Ruiz, Marcos Timon

Scope: Topics for discussion at the upcoming SRLM

Action: for discussion

The latest version of the agenda of the SRLM was presented. CAT members can send additional topics for the agenda to the Spanish delegation.

7.1.4. CAT 15th anniversary

CAT: Ilona Reischl

Scope: CAT activities in 2024 related to its 15th anniversary

Action: for discussion

Note: the first meeting of CAT took place in January 2009

A fist reflection on specific activities for the 15th anniversary of the CAT took place.

It was agreed to include the 15-year activities in the CAT workplan for 2024 (see 7.6.1).

7.2. Coordination with EMA Scientific Committees

7.2.1. Update from the PCWP-HCPWP

Scope: Meeting summary of the PCWP-HCPWP that took place on 27 & 28 June 2023 and draft Agenda of the PCWP-HCPWP Joint meeting that will take place on 19 & 20 September 2023

Action: for information

The information was noted.
7.2.2. CAT-COMP working group meeting

CAT: Ilona Reischl

Scope: Feedback from the CAT-COMP working group meeting that took place on 4 September 2023

**Action:** for information

Dariusz Sladowski and Maura O’Donovan provided a short feedback on the scientific and regulatory discussion that took place at the CAT-COMP working group meeting.

7.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

7.3.1. Patient Experience Data (PED) project

Scope: PED community is to develop a reflection paper on the EU approach to collect and analyse PED and coordinate the actions agreed at the workshop in Sep 2022.

**Action:** for information

CAT noted the presentation on the PED project. CAT members interested to participate in the develop of the reflection paper on the EU approach to collect and analyse PED should inform CAT secretariat.

7.3.2. Streamlining of BWP operations

Scope: Discontinuation of systematic discussions of ATMP quality variations

**Action:** for discussion

CAT noted the proposal from BWP to discuss quality type II variations for ATMPs based on a risk-based approach. The criteria for selection of procedures for BWP discussion were presented.

7.4. Cooperation with the EU regulatory network

7.4.1. Support to member states for the assessment of ATMP Marketing Authorisation Applications

CAT: Ilona Reischl

Scope: General discussion on needs and start of survey on resources (ATMP assessors) available in the NCAs

**Action:** for discussion

This topic will be discussed in an ad-hoc CAT meeting on 19.09.2023.
7.5. **Cooperation with international regulators**

**7.5.1. ATMP cluster teleconference with US-FDA, Health Canada and PMDA (Japan)**

CAT: Ilona Reischl  
Scope: Agenda of the teleconference that will take place on 28.09.2023  
**Action:** for information

The agenda topics proposed by FDA and Health Canada were presented and agreed. The remaining CAT topic from the previous ATMP cluster meeting will be postponed due to unavailability of the CAT Rapporteur.

**7.5.2. WHO considerations in developing a regulatory framework for human cells and tissues and for advanced therapy medicinal products**

CAT: Ilona Reischl  
Scope: Final Considerations document (adopted March 2023)  
**Action:** for information

The information was noted.

**7.5.3. International Pharmaceutical Regulatory Programme (IPRP): Gene therapy and Cell therapy working groups**

CAT: Pille Säälik  
Scope: Merger of the gene therapy and cell therapy working groups  
**Action:** for information

The information on the merger of the gene therapy and cell therapy working groups was noted. CAT was also informed that Ivana Haunerova is standing down as CAT representative for the cell therapy working group. Pille Säälik confirmed that she will continue as CAT representative for the (joined) IPRP gene and cell therapy working group.

7.6. **CAT work plan**

**7.6.1. CAT work plan for 2024**

CAT: Ilona Reischl  
Scope: First reflection on work plan topics for 2024  
**Action:** for discussion

CAT discussed the activities from the work plan for 2023 and identified those that are likely to be included in the CAT work plan for 2024. Additional work plan topics were discussed (including those linked to the 15-year anniversary).
7.6.2. CAT Stakeholder meeting of 16 May 2023

CAT: Ilona Reischl
Scope: Draft minutes of the CAT stakeholder meeting
Action: for adoption
The minutes of the CAT stakeholder meeting were adopted.

7.7. Planning and reporting

7.7.1. Business Pipeline Report

Scope: Q3/2023 Update of the Business Pipeline report for the human scientific committees
Action: for information
The information was noted.

7.8. Others

7.8.1. FDA Public workshop: Assessing genetic heterogeneity in the context of genome editing off-targets in gene therapy products

CAT: Ilona Reischl
Scope: Summary of the FDA public workshop that was held on 16 December 2022
Action: for information
The information was noted.

7.8.2. CASSS China – 3rd CMC Strategy Forum for Biological Products (12-13 October 2023)

CAT: Ilona Reischl
Scope: Request for a speaker
Action: for information
CAT members interested to take part in the CASSS China strategic forum should inform the CAT Secretariat.

7.8.3. FDA Considerations for the Use of Real-World Data and Real-World Evidence to Support Regulatory Decision-Making for Drug and Biological Products

CAT: Ilona Reischl
Scope: Guidance of industry published on FDA website (August 2023)
Action: for information
The FDA considerations document was noted.

8. Any other business

No item

Date of next CAT meeting:
04-06 October 2023

9. List of participants

Including any restrictions with respect to involvement of members / alternates / experts following evaluation of declared interests for the 06-08 September 2023 meeting.

<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
<th>Member State or affiliation</th>
<th>Outcome restriction following evaluation of e-DoI</th>
<th>Topics on agenda for which restrictions apply</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ilona Reischl</td>
<td>Chair</td>
<td>Austria</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Silke Dorner</td>
<td>Member</td>
<td>Austria</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Corina Spreitzer</td>
<td>Alternate</td>
<td>Austria</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Claire Beuneu</td>
<td>Member</td>
<td>Belgium</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Olga Kholmanskikh</td>
<td>Alternate</td>
<td>Belgium</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Rozalina Kulaksazova</td>
<td>Member</td>
<td>Bulgaria</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Azra Selimovic</td>
<td>Member</td>
<td>Croatia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Rafaela Pontou</td>
<td>Member</td>
<td>Cyprus</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Isavella Kyriakidou</td>
<td>Alternate</td>
<td>Cyprus</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Petr Soukup</td>
<td>Member</td>
<td>Czechia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Kristyna Rehorova</td>
<td>Alternate</td>
<td>Czechia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Hradilkova</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ebru Karakoc Madsen</td>
<td>Member</td>
<td>Denmark</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Bibi Fatima Syed Shah</td>
<td>Alternate</td>
<td>Denmark</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Toivo Maimets</td>
<td>Member</td>
<td>Estonia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Pille Saalik</td>
<td>Alternate</td>
<td>Estonia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Role</td>
<td>Member State or affiliation</td>
<td>Outcome restriction following evaluation of e-DoI</td>
<td>Topics on agenda for which restrictions apply</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>------------------------------------</td>
<td>----------------------------</td>
<td>---------------------------------------------------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>Heli Suila</td>
<td>Member</td>
<td>Finland</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Violaine Closson Carella</td>
<td>Member</td>
<td>France</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Jean-Michel Race</td>
<td>Alternate</td>
<td>France</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Jan Mueller-Berghaus</td>
<td>Member (CHMP co-opted member)</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Egbert Flory</td>
<td>Alternate (to CHMP representative)</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Maria Gazouli</td>
<td>Member</td>
<td>Greece</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Angeliki Rompoti</td>
<td>Alternate</td>
<td>Greece</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Maura O'Donovan</td>
<td>Member</td>
<td>Ireland</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Niamh Curran</td>
<td>Alternate</td>
<td>Ireland</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Concetta Quintarelli</td>
<td>Member</td>
<td>Italy</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Barbara Bonamassa</td>
<td>Alternate</td>
<td>Italy</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Una Riekstina</td>
<td>Member</td>
<td>Latvia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Raimondas Benetis</td>
<td>Alternate (to CHMP representative)</td>
<td>Lithuania</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Nancy De Bremaeker</td>
<td>Member</td>
<td>Luxembourg</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Anthony Samuel</td>
<td>Alternate (to CHMP representative)</td>
<td>Malta</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Johannes Hendrikus Ovelgonne</td>
<td>Member</td>
<td>Netherlands</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Dariusz Sladowski</td>
<td>Member</td>
<td>Poland</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Maria Isabel Borba Vieira</td>
<td>Alternate (to CHMP representative)</td>
<td>Portugal</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Silviu Istrate</td>
<td>Member</td>
<td>Romania</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Katarina Vavrová</td>
<td>Member</td>
<td>Slovakia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Margareta Fogelová</td>
<td>Alternate</td>
<td>Slovakia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Metoda Lipnik-Stangelj</td>
<td>Member</td>
<td>Slovenia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Role</td>
<td>State or affiliation</td>
<td>Outcome restriction following evaluation of e-DoI</td>
<td>Topics on agenda for which restrictions apply</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>-------------------------------------</td>
<td>----------------------</td>
<td>--------------------------------------------------</td>
<td>------------------------------------------------</td>
</tr>
<tr>
<td>Suzana Vidic</td>
<td>Alternate</td>
<td>Slovenia</td>
<td>No participation in final deliberations and voting on:</td>
<td>2.11.9 Kymriah II/72 2.11.12 Zolgensma II/40 2.13.2 Kymriah LEG/021</td>
</tr>
<tr>
<td>Sol Ruiz</td>
<td>Member (CHMP co-opted member)</td>
<td>Spain</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Marcos Timón</td>
<td>Alternate (to CHMP representative)</td>
<td>Spain</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Maria Luttgen</td>
<td>Member</td>
<td>Sweden</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Charlotte Anderberg</td>
<td>Alternate</td>
<td>Sweden</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Alessandra Renieri</td>
<td>Alternate</td>
<td>Clinicians' Representative</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Kerstin Solerbrant Melefors</td>
<td>Member</td>
<td>Patients' Representative</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Mencia de Lemus Belmont</td>
<td>Alternate</td>
<td>Patients' Representative</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Kieran Breen</td>
<td>Member (Vice-Chair)</td>
<td>Patients' Representative</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Catherine Milne</td>
<td>Observer/Alternate</td>
<td>EDQM</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Torbjorn Callreus</td>
<td>Expert</td>
<td>Malta</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Brigitte Müller</td>
<td>Expert</td>
<td>Austria</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Philipp Janesch</td>
<td>Expert</td>
<td>Austria</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Hanna Kankkonen</td>
<td>Expert</td>
<td>Finland</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Tia Hirvonen</td>
<td>Expert</td>
<td>Finland</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Paula Grönroos</td>
<td>Expert</td>
<td>Finland</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Karri Penttilä</td>
<td>Expert</td>
<td>Finland</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Johanna Lähteenvuoo</td>
<td>Expert</td>
<td>Finland</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Martina Schüßler-Lenz</td>
<td>Expert</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Beate Mosl</td>
<td>Expert</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Juliane Rau</td>
<td>Expert</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Role</td>
<td>Member State or affiliation</td>
<td>Outcome restriction following evaluation of e-DoI</td>
<td>Topics on agenda for which restrictions apply</td>
</tr>
<tr>
<td>--------------------------</td>
<td>------------</td>
<td>----------------------------</td>
<td>---------------------------------------------------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>Attila Sebe</td>
<td>Expert</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Odoardo Olimpieri</td>
<td>Expert</td>
<td>Italy</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Antonella Isgrò</td>
<td>Expert</td>
<td>Italy</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Federico De Angelis</td>
<td>Expert</td>
<td>Italy</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Sean Barry</td>
<td>Expert</td>
<td>Ireland</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Silke Schüle</td>
<td>Expert</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Denise Tischner</td>
<td>Expert</td>
<td>Germany</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Boje Kvorning Pires Ehmsen</td>
<td>Expert</td>
<td>Denmark</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Torsten Holm Nielsen</td>
<td>Expert</td>
<td>Denmark</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Carolina Prieto</td>
<td>Expert</td>
<td>Spain</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Macarena Gajardo</td>
<td>Expert</td>
<td>Spain</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Katrin Féchir</td>
<td>Expert</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Silvia Vogl</td>
<td>Expert</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Johanna Reul</td>
<td>Expert</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Gaëlle De Meyer</td>
<td>Expert</td>
<td>Belgium</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
</tbody>
</table>

Meeting run with support from relevant EMA staff
10. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

For a list of acronyms and abbreviations, see: List of abbreviations used in EMA human medicines scientific committees and CMDh documents, and in relation to EMA’s regulatory activities

Evaluation of ATMPs (section 2)

This section lists applications for marketing authorisations of new Advanced Therapy Medicinal Products (ATMPs) that are to be discussed by the Committee. It also lists Post-authorisation activities (section 2.11-2.13) and any ATMP related inspection requests (section 2.14).

New applications (sections 2.1 to 2.9.)

Section 2.1 is for ATMPs nearing the end of the evaluation and for which the CAT is expected to adopt a draft opinion at this meeting on whether marketing authorisation should be granted. Once adopted, the CAT opinion is transmitted to the CHMP for final adoption. The CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU. More information on the evaluation of ATMPs can be found here.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:

The assessment of an application for a new medicine takes up to 210 ‘active’ days. This active evaluation time is interrupted by at least one ‘clock-stop’ during which time the applicant prepares the answers to questions from the CAT. The clock stop happens after day 120 and may also happen after day 180, when the CAT has adopted respectively a Day 120 list of questions (section 2.4) or a List of outstanding issues to be addressed by the company, which is listed in the agenda under sections 2.7 (Ongoing evaluation procedures (section 2.3). Section 2.6 also includes the CAT discussions at any other timepoint of the evaluation procedure of new applications.

Oral explanation (section 2.2.)

Prior to adoption of the CAT opinion, marketing authorisation applicants are normally invited to the CAT plenary meeting to address questions raised by the Committee.

Oral explanations normally relate to ongoing applications, but they can also relate to any other issue for which the CAT would like to discuss with company representatives in person.

New applications (section 2.7.)

In this section, information is included on upcoming marketing authorisation applications for ATMPs, as well as information on appointment of Rapporteurs for new ATMP applications.
Withdrawal of applications (section 2.8.)

This section includes information on marketing authorisation applications that are withdrawn by the applicant. Applicants may decide to withdraw applications at any stage during the assessment and a CAT opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 (section 2.9.)

This section lists applications for new marketing authorisation for ATMPs for which the applicant has requested a re-examination of the opinion previously issued by the CHMP. Similar to the initial evaluation of a marketing authorisation of an ATMP, CAT will adopt a draft re-examination opinion, which is transmitted to the CHMP for final adoption.

Companion diagnostics (section 2.10)

This section lists applications for initial and follow-on consultation of companion diagnostics.

Post-authorisation activities (section 2.11-2.13.)

Section 2.11 lists type II variations, including extension of indication applications and re-examination procedures for type II variations for which the applicant has requested re-examination of the opinion previously issued by the CHMP. Section 2.12 list extension application according to Annex I of Reg. 1234/2008 and section 2.13 includes all other post-authorisation activities concerning authorised ATMPs that are not covered elsewhere in the agenda such as post-authorisation measures, annual reassessments, 5-year renewals, supply shortages, quality defects. Issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines, will also be included here.

GMP and GCP Inspections Issues (section 2.14.)

This section lists inspections that are undertaken for ATMPs. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Certification of ATMPs (section 3)

This section includes the scientific evaluation by the CAT of quality and non-clinical data that small and medium-sized enterprises have generated at any stage of the ATMP development process. More information on the ATMP certification procedure can be found here.

Scientific Recommendation on Classification of ATMPs (Section 4)

This section includes the scientific recommendation by the CAT on whether medicines based on genes, cells or tissues meet the scientific criteria that define ATMPs. More information on the ATMP classification procedure, including the outcomes of finalised classifications, can be found here.

Scientific Advice (section 5)

This section includes all scientific advice given to companies during the development of an ATMP. Information related to the number of ATMP related scientific advices discussed by CAT can be found in the CAT Monthly reports. Further information on SAWP can be found here.

Pre-Authorisation (section 6)

Paediatric Investigation Plan (PIP)

This section includes the discussion of an ATMP before a formal application for marketing authorisation
is submitted. These cases refer for example to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation: in case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

CAT contributes to the evaluation of a Paediatric Investigation Plan (PIPs) for ATMPs by the Paediatric Committee. These PIPs are included in this section of the Agenda.

**ITF Briefing meeting in the field of ATMPs**

This section refers to briefing meetings of the Innovation Task Force and International co-operations activities of the CAT

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes of meetings with applicants developing ATMPs and of other ITF meetings of interest to the CAT are included in this section of the agenda. Further information on the ITF can be found here.

**Priority Medicines (PRIME)**

This section includes the new requests for eligibility to PRIME for ATMPs under development, the discussions in CAT of these eligibility requests and the final recommendations for eligibility of ATMPs adopted by CHMP.

CAT will appoint one of its members as the CAT sponsor for each new ATMP eligibility request who will lead the CAT discussion based on the recommendation from the SAWP.

**Organisational, regulatory and methodological matters (section 7)**

This section includes topics related to regulatory and procedural guidance, CAT workplan, CAT meeting organisation (including CAT membership), planning and reporting, co-ordination with other committees, working parties and scientific advisory groups.

Furthermore, this section refers to the activities of the CAT drafting groups developing scientific guidelines for gene therapy medicinal products and for cell-based medicinal products, cooperation within the EU regulatory network and international regulators as well as direct interaction with interested parties. It also includes topics of scientific interest for the Committee that are not directly related to the work of the CAT drafting groups or CAT associated working parties.

**Any other business (section 8)**

This section is populated with miscellaneous topics not suitable under the previous headings.

More detailed information on the above terms can be found on the EMA website: [www.ema.europa.eu](http://www.ema.europa.eu/)